Tsrl, Inc.
Publicly observedAnn Arbor, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Ann Arbor | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Tsrl, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | TP74UMNGJDJ1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant3 Sept 2026Publicly observed
NIH SBIR/STTR award: Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy Subjects
USD 999,298.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant16 Aug 2024Publicly observed
NIH SBIR/STTR award: Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
USD 999,975.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant19 Sept 2022Publicly observed
NIH SBIR/STTR award: Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease
USD 1,097,498.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant19 Sept 2022Publicly observed
NIH SBIR/STTR award: Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease
USD 1,097,498.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 Aug 2017Publicly observed
NIH SBIR/STTR award: Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
USD 999,765.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.